Neutropenia - Pipeline Review, H1 2018

Publication ID:

GMD0318089

Publication Date:

March 20, 2018

Pages:

106

Publisher:

Global 麻豆原创s Direct

Countries:

Global [1]

USD 2,000.00

Drug Pipeline [2]

Pharma & Healthcare [3]

Description:

Neutropenia - Pipeline Review, H1 2018

Summary

Global 麻豆原创s Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neutropenia - Pipeline Review, H1 2018, provides an overview of the Neutropenia (Hematological Disorders) pipeline landscape.

Neutropenia is an abnormally low count of neutrophils, a type of white blood cell that helps fight off infections, particularly those caused by bacteria and fungi. Signs and symptoms include fevers, frequent infections, mouth ulcers, gum infections and dysuria.

Report Highlights

Global 麻豆原创s Direct's Pharmaceutical and Healthcare latest pipeline guide Neutropenia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Neutropenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neutropenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 2, 4, 8, 8, 1 and 2 respectively.

Neutropenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global 麻豆原创s Direct鈥檚 proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Neutropenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Neutropenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neutropenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neutropenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neutropenia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neutropenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it鈥檚 most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neutropenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents:

Table of Contents
List of Tables
List of Figures
Introduction
Global 麻豆原创s Direct Report Coverage
Neutropenia - Overview
Neutropenia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Neutropenia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neutropenia - Companies Involved in Therapeutics Development
Adello Biologics LLC
Arven Ilac
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Cantex Pharmaceuticals Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cleveland BioLabs Inc
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eurofarma Laboratorios SA
Ligand Pharmaceuticals Inc
Lupin Ltd
Merck & Co Inc
Mycenax Biotech Inc
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd
Neutropenia - Drug Profiles
ACN-8337 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARVMIC-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBLB-612 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dociparstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
filgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein for Neutropenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LG-7455 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nova-GM-CSF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegfilgrastim biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plinabulin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
posaconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
romyelocel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-853 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neutropenia - Dormant Projects
Neutropenia - Discontinued Products
Neutropenia - Product Development Milestones
Featured News & Press Releases
Nov 30, 2017: European Medicines Agency Accepts 麻豆原创ing Authorization Applications for Mylan and Biocon's Proposed Biosimilars Pegfilgrastim
Nov 07, 2017: Biocon: Resubmission of Pegfilgrastim Dossier with EMA
Sep 15, 2017: Mylan Announces Withdrawal of the marketing authorisation application for Fulphila (pegfilgrastim)
Sep 11, 2017: FDA Accepts Adello Biologics Biosimilar Biologics License Application for a Proposed Filgrastim Biosimilar
Jun 12, 2017: Coherus Biosciences Receives Complete Response Letter From FDA for Its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
Apr 25, 2017: Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar
Jan 27, 2017: Withdrawal of the marketing authorisation application for Zioxtenzo (pegfilgrastim)
Dec 16, 2016: Withdrawal of the marketing authorisation application for Cavoley (pegfilgrastim)
Dec 16, 2016: Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim)
Nov 01, 2016: Prolong Pharmaceuticals Presents Data on Toxicology, Pharmacokinetics and Pharmacodynamics of ANF-RHO
Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
Jul 21, 2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
Jul 21, 2016: Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
List of Tables
Number of Products under Development for Neutropenia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Neutropenia - Pipeline by Adello Biologics LLC, H1 2018
Neutropenia - Pipeline by Arven Ilac, H1 2018
Neutropenia - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018
Neutropenia - Pipeline by Biocon Ltd, H1 2018
Neutropenia - Pipeline by Cantex Pharmaceuticals Inc, H1 2018
Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2018
Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018
Neutropenia - Pipeline by Cleveland BioLabs Inc, H1 2018
Neutropenia - Pipeline by Coherus BioSciences Inc, H1 2018
Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2018
Neutropenia - Pipeline by Eurofarma Laboratorios SA, H1 2018
Neutropenia - Pipeline by Ligand Pharmaceuticals Inc, H1 2018
Neutropenia - Pipeline by Lupin Ltd, H1 2018
Neutropenia - Pipeline by Merck & Co Inc, H1 2018
Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2018
Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2018
Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2018
Neutropenia - Pipeline by Sandoz International GmbH, H1 2018
Neutropenia - Pipeline by USV Pvt Ltd, H1 2018
Neutropenia - Dormant Projects, H1 2018
Neutropenia - Dormant Projects, H1 2018 (Contd..1), H1 2018
Neutropenia - Discontinued Products, H1 2018

List of Figures
List of Figures
Number of Products under Development for Neutropenia, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

Companies Mentioned:

Adello Biologics LLC
Arven Ilac
BeyondSpring Pharmaceuticals Inc
Biocon Ltd
Cantex Pharmaceuticals Inc
Cellerant Therapeutics Inc
Chong Kun Dang Pharmaceutical Corp
Cleveland BioLabs Inc
Coherus BioSciences Inc
Dr. Reddy's Laboratories Ltd
Eurofarma Laboratorios SA
Ligand Pharmaceuticals Inc
Lupin Ltd
Merck & Co Inc
Mycenax Biotech Inc
Prolong Pharmaceuticals LLC
Richter Gedeon Nyrt
Sandoz International GmbH
USV Pvt Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.